November 2012 - Page 3 of 15

WednesdayNov 28, 2012 5:00 pm

San Fran’s BART Places Order for 270 AXION International (AXIH) Switch Ties

AXION International Holdings, a green technologies company, today said it has received its third purchase order for an additional 270 ECOTRAX™ switch ties from San Francisco Bay Area Rapid Transit (BART). BART will install the switch ties along its 104 miles of tracks that connect San Francisco with the suburbs. The heavy-rail public transit and subway system is the 5th busiest rapid transit system in the U.S. ECOTRAX ties are made from AXION’s patented 100 percent recycled plastic formulation. Because they are inert, the ties are not subject to rotting or absorption of moisture or insect infestation. “To put this…

WednesdayNov 28, 2012 11:49 am

Vermillion, Inc. (VRML) Appoints Bruce Huebner as Interim CEO

Vermillion, a molecular diagnostics company, announced that director Bruce A. Huebner has been appointed as interim CEO. He is following Gail S. Page, the company’s most recent CEO, who will assist in the transition and serve as a strategic advisor. Mr. Huebner will continue to serve on the board of directors as he assumes his new role. Mr. Huebner has executive management experience in multiple clinical diagnostic companies, including Osmetech Molecular Diagnostics, Nanogen, and Gen-Probe. While serving as president of Osmetech, he successfully established the company as a fully integrated business, obtaining FDA clearance for four molecular diagnostic microarray products…

TuesdayNov 27, 2012 5:22 pm

EntreMed, Inc. (ENMD) Announces Publication of Results of Breast Cancer Preclinical Study

EntreMed, a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer, announced the publication of favorable results of a preclinical study in breast cancer of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. The article is titled “Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models.” The reports state findings that ENMD-2076 was able to provide anticancer activity against breast cancer cell lines lacking expression of the estrogen receptor (ER), progesterone receptor (PR) and without HER2‑amplification. Candidate predictive biomarkers were also identified which may be useful in selecting patients that are…

TuesdayNov 27, 2012 5:21 pm

Prana Biotechnology Ltd. (PRAN) Completes Patient Enrollment in Alzheimer Trial

Australia-based Prana Biotechnology is focused on commercializing research into age-related neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. The company’s research centers on the interactions between certain metals in the human body and proteins. The company announced today that it has completed enrollment in the IMAGINE trial, a 12-month Phase II trial testing PBT2, the company’s drug in development for Alzheimer’s disease. This disease affects more than 26 million people around the globe. All currently available treatments only offer some degree of symptomatic relief, but none change the course of the disease. PBT2 has the potential to actually treat…

TuesdayNov 27, 2012 5:20 pm

Shoreline Energy Corp. (SEQ.TO) to Provide Investor Update via Conference Call Tomorrow

Shoreline Energy Corp. is planning to hold a conference call tomorrow, November 28, 2012, to discuss its recent business developments, including the impact and outlook relating to its acquisition of the Wattenberg Colorado Project located in the Denver-Julesberg Basin. The Wattenberg Colorado Project represents Shoreline’s initial entry into the United States. This project is currently an area of a large scale, low risk horizontal development well program, using multi-stage frac technology. Acquisition of the project is expected to generate $4.6m of cash flows the first year, providing an initial rate of return of more than 30%. The CEO of Shoreline…

TuesdayNov 27, 2012 5:19 pm

International Stem Cell Corp. (ISCO) Faces Huge Therapeutic Market

International Stem Cell Corp., developers of human parthenogenic stem cells (hpSCs), a new class of non-embryonic stem cells that has the best characteristics of each of the other classes of stem cells, is focused on using hpSCs to treat severe diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe, immune-matched human cells. Parthenogenic stem cells hold great promise for stem cell regenerative medicine by addressing the critical issue of immune-rejection, the problem of finding cells that have the right chemical structure so as not…

TuesdayNov 27, 2012 5:11 pm

Gemini Explorations, Inc. (GMXS) Possesses High Grade Gold Projects in Underexplored and Underdeveloped Colombian Districts

Gemini Explorations has secured some exciting acquisitions in the largely underdeveloped mineral reserve wealth of Colombia, drawing on nearly two decades of connections within the industry in order to turn GMXS into the next big name among juniors in South American gold production. The superb geological potential of the company’s two current projects, the La Planada and La Tapada gold properties, shows how intelligent the company’s management is, snapping up such richly mineralized acreage in key underdeveloped gold districts. GMXS even formed a Colombian subsidiary, Minera Gemini SA, back in May of this year to streamline/facilitate operations and act as…

MondayNov 26, 2012 5:55 pm

MediciNova, Inc. (MNOV) Receives Notice of European Patent Allowance for MS drug

MediciNova received a notice of allowance from the European Patent Office for a pending patent application which covers the use of ibudilast (MN-166) for the treatment of progressive forms of multiple sclerosis (MS). MN-166 is the company’s drug development candidate for certain neurological conditions, including progressive MS, drug addiction, and pain. Patents maturing in this type of application are not expected to mature before 2029 and will cover multiple methods of treating primary or secondary progressive MS. “Treatment options for patients who have progressive MS are very limited and assessing potential pharmacotherapies like ibudilast may offer real hope,” said Dr.…

MondayNov 26, 2012 5:54 pm

Loans4Less.com, Inc. (LFLS) Represents an Important Resource for Consumers

Loans4Less.com is intended to be a valuable source of mortgage and real estate information for individuals interested in residential mortgages, in addition to providing a user-friendly portal to the company’s own residential loan brokerage services. To this end, the company offers critical guidance on what consumers need to understand when seeking a mortgage loan. Regarding their own mortgage process, the company emphasizes the need for full and clear communication at all levels, an openness that is especially important and attractive to online viewers. Their stated aim is to make the mortgage decision process comfortable and straightforward by providing an honest…

MondayNov 26, 2012 5:53 pm

GlobalWise Investments, Inc. (GWIV) and Intellivue’s Unbeatable Mix

When it comes to the digitization, organization, and access of critical information, the key is simplicity and flexibility. Even to this day, companies and other organizations still find themselves trying to maintain two parallel worlds, one consisting of hard copy documents, and the other being computerized information stored online. Juggling data in both forms is hard enough without cumbersome technological requirements getting in the way. Any system designed to help get a handle on large volumes of documents must bring with it operational simplicity and flexibility, features that are the core of Intellivue, the Enterprise Content Management (ECM) system offered…

Site Search

Company Search

Month: November 2012